com_NN
Emoluments_NOMZ
of_PIN
Directors_NN
The_DT
aggregate_JJ
remuneration_NOMZ
,_,
excluding_VBG
pension_NN
contributions_NOMZ
,_,
paid_VBN
to_TO
or_CC
accrued_VBN
for_PIN
all_QUAN
Directors_NN
and_PHC
officers_NN
of_PIN
the_DT
Company_NN
for_PIN
services_NN
in_PIN
all_QUAN
capacities_NOMZ
during_PIN
the_DT
year_NN
ended_VBD
31_CD
December_NN
2004_CD
was_VBD [BEMA]
10_CD
million_CD
$_$
17_CD
million_CD
._.
Remuneration_NOMZ
of_PIN
individual_JJ
Directors_NN
is_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
in_PIN
sterling_GER
and_PHC
US_FPP1
dollars_NN
._.
All_QUAN
salaries_NN
,_,
fees_NN
and_PHC
bonuses_NN
for_PIN
Directors_NN
are_VPRT [PASS]
established_VBN [PRIV]
in_PIN
sterling_GER
._.
As_IN
described_VBN
fully_AMP
in_PIN
the_DT
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
and_CC
noted_VBD [PRIV]
on_PIN
page_NN
24_CD
of_PIN
the_DT
Annual_JJ
Review_NN
2004_CD
,_,
compensation_NOMZ
payments_NOMZ
to_PIN
Hkan_NN
Mogren_NN
and_PHC
ke_NN
Stavling_GER
were_VBD [BEMA]
450,000_CD
$_$
818,000_CD
and_CC
435,000_CD
$_$
791,000_CD
,_,
respectively_RB
and_CC
are_VPRT [PASS]
included_VBN
within_PIN
Other_JJ
in_PIN
the_DT
above_PLACE
tables_NN
._.
